POSB156 Cost-Utility Analysis of Crizanlizumab and Hydroxyurea in Preventing Vaso-Occlusive Events in Patients with Sickle-Cell Disease: A Lifetime Model from a Payer's and Societal Perspectives
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.429
https://www.valueinhealthjournal.com/article/S1098-3015(21)02224-5/fulltext
Title :
POSB156 Cost-Utility Analysis of Crizanlizumab and Hydroxyurea in Preventing Vaso-Occlusive Events in Patients with Sickle-Cell Disease: A Lifetime Model from a Payer's and Societal Perspectives
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02224-5&doi=10.1016/j.jval.2021.11.429
First page :
Section Title :
Open access? :
No
Section Order :
11209